Diligence memo · auto-generated · as of July 2, 2026
Ankasa Regenerative Therapeutics, Inc.
Ankasa Regenerative Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ankasa Regenerative Therapeutics, Inc. operates in Biotechnology, based in LA JOLLA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ankasa Regenerative Therapeutics, Inc. has raised $16M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.5M on 2015-05-29.
Most recent recorded round closed around 2020-09-30.
Valuation (modeled)modeled
Provath models Ankasa Regenerative Therapeutics, Inc. at approximately $192M (range $6.5M–$988M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.06× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era. Within the normal band (106% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 64 months.
Last raise 5.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 64% of Biotechnology peers (4293 compared).
Modeled value ranks above 72% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.